Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Antegren Brand Rejected Due To Possible Confusion With Ativan, Integrilin

This article was originally published in The Pink Sheet Daily

Executive Summary

Elan and Biogen Idec agreed to change the name of the multiple sclerosis monoclonal antibody natalizumab from Antegren to Tysabri after FDA expressed concern over potential drug name mix-ups

You may also be interested in...

Tysabri's Next Steps Include Rheumatoid Arthritis, Crohn's Indications

Elan/Biogen Idec may price the recently approved Tysabri at a premium to other multiple sclerosis therapies in anticipation of the additional indications. The price announcement could come within a few days.

Italy Leads European Push Into Conditional Reimbursement

Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts